Epigral Limited

BSE:543332 Stock Report

Market Cap: ₹84.8b

Epigral Past Earnings Performance

Past criteria checks 6/6

Epigral has been growing earnings at an average annual rate of 10.4%, while the Chemicals industry saw earnings growing at 14.6% annually. Revenues have been growing at an average rate of 11.8% per year. Epigral's return on equity is 21%, and it has net margins of 12.9%.

Key information

10.4%

Earnings growth rate

10.3%

EPS growth rate

Chemicals Industry Growth17.7%
Revenue growth rate11.8%
Return on equity21.0%
Net Margin12.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Epigral makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:543332 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2422,7342,9351,1460
30 Jun 2421,2552,5021,0850
31 Mar 2419,2921,9591,0190
31 Dec 2319,6671,9538870
30 Sep 2320,3312,2348710
30 Jun 2321,1042,7708650
31 Mar 2321,8843,5338860
31 Dec 2221,2503,7569240
30 Sep 2220,0933,6828950
30 Jun 2217,9343,2368480
31 Mar 2215,5092,5287680
31 Mar 218,2861,0085360
31 Mar 206,0981,1414410
31 Mar 197,1041,8284820
31 Mar 185,9751,5553710
31 Mar 173,9216651500
31 Mar 163,9826721200
31 Mar 153,5183471020

Quality Earnings: 543332 has high quality earnings.

Growing Profit Margin: 543332's current net profit margins (12.9%) are higher than last year (11%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 543332's earnings have grown by 10.4% per year over the past 5 years.

Accelerating Growth: 543332's earnings growth over the past year (31.4%) exceeds its 5-year average (10.4% per year).

Earnings vs Industry: 543332 earnings growth over the past year (31.4%) exceeded the Chemicals industry 8%.

Return on Equity

High ROE: 543332's Return on Equity (21%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:11
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Epigral Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBP Wealth Management Private Limited
Meet VoraEmkay Global Financial Services Ltd.
Kameswari V. S. ChavaliFirstCall Research